bcy 1

New insight in death signaling:on Fas and FasL

Bei-Chang Yang, Ph.D. (楊倍昌 )

Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University (NCKU), Tainan, Taiwan.

Research center for Society, Technology and Medicine (STM center); NCKU Tainan, Taiwan.

bcy 2

The term 'apoptosis' describes the molecular and morphological processes leading to controlled cellular self-destruction and was first introduced in a publication by Kerr, Wyllie and Currie.

Br. J. Cancer, 1972, 26: 239

bcy 3

Apoptosis 花瓣樹葉的凋零飄落'Apoptosis' (pronounced as əpo΄tosis ) is of Greek origin, having the meaning "falling off or dropping off", in analogy to leaves falling from trees or petals from flowers, sometimes also called as programmed cell death.

東豐路 , 台南

bcy 4

Some types of death: apoptosis, autophage, and necrosis

AUTOPHAGE

bcy 5

Detection of apoptotic cells

• Hoechst stain

• DNA ladder

• Comet assay

• TUNEL stain; immunohistochmical (terminal transferase)

• FACS analysis (Annexin V, MC540, propidium iodine for subG0, TUNEL)

bcy 6

• TNF receptor (1985)– Kull FC Jr.  Jacobs S.  Cuatrecasas P.

(1985) Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity. PNAS 82:5756-5760. 

• Fas (1989)– P Krammer group (1989): Trauth BC.  et al.  Monoclonal

antibody-mediated tumor regression by induction of apoptosis. Science  245(4915):301-305.

– S Nagata group (1991):   Itoh N.  et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243.

bcy 7

bcy 8

Shigekazu Nagata

For a man who spends most of his time thinking about death, Shigekazu Nagata is remarkably upbeat. For over a decade, he has been making a name for himself with research on apoptosis, the mechanism of programmed cell death, and during that time he has watched the field come alive.Nature Medicine  7, 759 (2001)

Peter H. Krammer, 2002

bcy 9

Caspase 3 Apaf-1Caspase 9Death substrates

Apoptosis

Nature 407, 789 – 795(2000)

Nagata, S. (Fas); Krammer, P. (Apo1)

CD95/CD95-L

Transducing death signal

Involving in cytotoxicity, immune homeostasis, tumor formation, etc.

bcy 10

Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.

Strand, S., W. J. Hofmann, H. Hung, M. Muller, G. Otto, D. Strand, S. M. Martani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95(APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion ? Nature Med. 2:1361.

O’Connell, J., G. C. O’Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.

Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nature Med. 3:165.

O’Connell, J., M. W. Bennett, G. G. O’sullivan, D. Roche, J. Kelly, J. K. Collins, and F. Shanahan. 1999. Fas counter-attack the best form of tumor defense? Nature Med. 5:267.

Seino, K. I., N. Kayagaki, N. Tsukada, K. Fukao, H. Yagita, and K. Okumura. 1997. Transplantation of CD95 ligand-expressing grafts. Influence of transplanation site and difficulty in protecting allo- and xenigrafts. Transplantation 64:1050.

Fas counterattack mechanism

bcy 11

Nat Med  5:267 (1999); Nat Med 7:271 (2001)

Joe O'Connell, et al. Fas counter-attack- the best form of tumor defense?

Many tumor cells express FasL

Tumor

bcy 12

Immune privilege or inflammation? Joe O'Connell et al. Nature Medicine 7, 271 - 274 (2001)

bcy 13

In vivo consequences of FasL expression by tumors

(using over-expression system)

Enhanced rejection Delayed rejection

Renca, MH134, L5178Y, B16/BL6, CT26*

Note: *:syngenic, nude, SCID #: allogenic, lpr

Ref: Lejeune FJ et al., 1998, Curr. Op. Immunol.

CT26#

B16-F10

bcy 14

Animal model

C57B/6 Melanoma cell line

B6F10 Gene knockdown by

FasL ribozyme Subcutis/lung

bcy 15

FasLribozyme/EGFP plasmid

Hammerhead ribozyme.

54-mers. Inserted into the

pEGFP-N1. Driven by CMV

promoter.

Chio CC, Wang YS, Chen YL, Lin SJ and Yang BC (2001) Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumor infiltrating cells, and liver damage but accelerates tumor formation in nude mice.

Br J Cancer 85:1185-1192

bcy 16

Effect of FasL on growth and death of B16F10 cells

Apoptosis in 3-day cultureCell growth rate

bcy 17

Granulocytes mediates the Fas-L-associated apoptosis during lung metastasis of melanoma that determines the metastatic behavior (B16F10 in C57BL/6)

Br J Cancer, 87: 359 (2002)

bcy 18

Depletion of CD4, CD8 T cells and PMNs affected lung metastasis

4410

41 357 95154

Vector controls Fas-Lribozyme

What happened here?Br J Cancer, 87: 359 (2002)

bcy 19

Control

Fas-Lribozyme

In subcutaneous environment: FasL on tumor cells mediates inactivation of neutrophils

5x105cells subcutaneous injection

FasL on tumor cells mediates inactivation of neutrophils. J. Immunol. (2003) 171:1183-1192

bcy 20

Vector controls Fas-L-ribozyme

Depletion of CD4, CD8 T cells and PMNs affected subcutaneous tumor formation

bcy 21

Tumor FasLhigh impairs neutrophil activation: gelatinase B, ROS, CD-11b, and FasL (In coculture for 24 h).

Cell death

Gelatinase B ROS

J. Immunol. (2003) 171:1183-1192

bcy 22

The action of FasL:

It is organ dependent!

bcy 23

Granulocytes mediates the Fas-L-associated apoptosis during lung metastasis of melanoma that determines the metastatic behavior (B16F10 in C57BL/6) Br J Cancer, 87: 359 (2002)

i.v. 5 x 105 cells /mouse; Observed at day 14; (bar = 1 cm)

Voice against Fas counter attack mechanism:

Kang, S. M. et al. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3:738.

bcy 24

Ryan AE,1 Shanahan F, O’Connell J, and Houston AM (2005)Addressing the ‘‘Fas Counterattack’’ Controversy: Blocking FasLigand Expression Suppresses Tumor Immune Evasion of Colon Cancer In vivo. Cancer Res 65: 9817-9823 (困獸之鬥 ?)

• Figure 1. FasL antisense RNA suppresses FasL expression by CMT93 cells.

• Figure 2. Effect of reduced FasL expression by CMT93 cells on tumor development.

• Figure 3. Analysis of tumors derived from CMT93/AS, CMT93/C and parental cells inoculated s.c. in C57BL/6 mice.

• Figure 4. Down-regulation of FasL expression leads to increased infiltration of TILs.

• Figure 5. Constitutively expressed FasL does not trigger neutrophil recruitment in vivo.

No Fas-mediated apoptosis at all! What Joe O’Connell was thinking then? Increase in Th17 cells

bcy 25

FasL reverse signaling

Suzuki I. and Fink PJ.. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med., 187:123, 1998.

Boursalian TE, Fink PJ, Mutation in Fas Ligand Impairs Maturation of Thymocytes Bearing Moderate Affinity T Cell Receptors, J. Exp. Med., 198, 349, 2003.

Sun M, Ames KT, Suzuki I,. Fink PJ, The Cytoplasmic Domain of Fas Ligand Costimulates TCR Signals, J. Immunol., 177, 1481, 2006.

Pamela J. Fink, h.D.

Department of Immunology

University of Washington

bcy 26

The structure of FasL

bcy 27

The cytoplasmic domain of FasL is sufficient to mediate costimulation.

A, Murine FasL and (CD3)

fusion constructs encode an N-terminal myristylation motif (M) that tethers the molecules to the membrane, the relevant cytoplasmic domains, FKBP3, and a C-terminal HA epitope. The addition of FK1012 or AP1510 induces hetero-oligomers of these membrane-bound proteins. B, Jurkat cells cotransfected with combinations of CID constructs, firefly luciferase reporter (NFAT or AP-1) and Renilla luciferase reporter (pRL-TK) were subjected to CID analysis.

J. Immunol., 177, 1481, 2006

bcy 28

(A). Full-length and truncated FasL. Adapted from Orlinick JR, et al. J Biol Chem 1997, 272:32221-29. Jodo S, et al. J Immunol 2005, 174:4470-4474. FasL-

70: deleting the N-terminal 2-70 aa; FasL- 33: deleting the N-terminal 2-33 aa. △ △

Ectopic expression of FasL in NIH3T3

bcy 29

Nude mice were injected with 5x105 cells of NIH3T3 cells carrying FasL as indicated via tail vein. After 4 weeks, spontaneous transformed NIH3T3 tumor nodules formed in the lung. Ling sections were stained with H/E. Tumor nodules show dark purple stain.

Full-length FasL suppresses lung metastasis, while truncated FasL promotes tumor formation.

bcy 30

FasL 33 and FasL 70 enhanced anchorage-independent growth. 1.5 ×10△ △ 4 cells were cultured in 0.3% noble agar for 2-3 weeks. Foci were observed under a microscope. Representative shape of colony (x100) was shown (A). Number of foci was counted (B). Values was shown the mean ± SEM. (* p<0.05 compared with N1).

Truncated FasL promote cell transformation (enhances anchorage-indecent growth)

bcy 31

In the single cell motility assay, cell migration distance in 6 h was recorded every 5 min by time lapse video under a microscope. Total distance of cell migration was taken to represent cell mobility. (C) In invasion assay, cells were seeded on matrigel (1 mg/ml) coated transwell plates in 16 h. Invading cells were calculated for quantification. Values was shown the mean ± SEM. (* p<0.05, ** p<0.001 compared with N1, # p<0.05 compared with FasL)

FasL enhances cell migration and invasion.

bcy 32

Phospho-STAT3 and STAT3 were analyzed by Western blot (B). Cells were incubated in 1% FBS in 16 h and detected the expressions of cyclin D1 by Western blotting (C) and RT-PCR (D).

bcy 33

Cell membrane

Full-length FasL

Inhibitory signal regulating immune responses

FasL-△70

Stat3, cyclinD1

ERK, PI3K

FasL reverse signal, A speculation

?

CK1

PRD

bcy 34

bcy 35

bcy 36

bcy 37

A proposed FasL-Met signal pathway.

bcy 38

Do you still believe in Fas counter- attack mechanism?

bcy 39

Nature is working in a way that is not always as been told.